Hemophilia: Hereditary Bleeding disorder caused by deficiency of a coagulation factor.
血友病：一种遗传性出血性疾病，因先天性缺乏某种凝血因子而引起。
Coagulation factor analyzer is used to detect content of coagulation factor in human's blood.
凝血因子分析仪就是用来检测人体血液中所含有凝血因子含量的仪器。
The invention relates to novel compounds with formula (I) useful as blood coagulation factor inhibitors.
本发明涉及新的式（I）化合物，其用作凝血因子抑制剂。
Objective to investigate the relationship between coagulation factor VII (FVII) activity and polymorphism.
目的探讨凝血因子VII (FVII)活性与其多态性的关系。
Coagulation factor analyzers are more and more welcomed by hospitals, laboratories and the testing agencies.
凝血因子分析仪也就越来越受到医院、实验室及各检测机构的欢迎。
Objective to explore the clinical significance of coagulation factor and fibrinolytic indexes in viral hepatitis and pregnant hepatitis.
目的探讨凝血因子和纤溶指标在病毒性肝炎和妊娠肝炎中的变化和意义。
Coagulation factors can be removed from plasma and may be used to treat people with coagulation factor deficiencies, such as hemophilia.
凝血因子能够从血浆中分离，用于治疗凝血因子缺乏的患者，如血友病。
Meanwhile, ameliorating hypoxia, using proper anticoagulant and supplying blood coagulation factor would help homeostatic function recovery.
改善缺氧，适当适时应用抗凝药物和补充凝血因子有助于止血功能的恢复。
On the basis of the experimental research coagulation factor expressing the coagulation characteristics of aggregates in powder is proposed.
根据实验，提出了用以表征粉末中团粒聚集特征的聚集系数的概念。
OBJECTIVE:To summarize the safety and validity of coagulation factor replacement in hemophilic arthritis patients undergoing total knee arthroplasty(TKA).
目的：观察血友病关节炎患者行人工膝关节置换围手术期凝血因子替代治疗的安全性和有效性。
Objective:To improve the skills of diagnosing severe hemophilia A(HA)and the carriers of the disease by detection of coagulation factor VIII(FVIII)gene inversion.
目的：检测凝血因子VIII基因倒位，提高对重型血友病A患者及其携带者的诊断水平。
Recent studies have showed tissue factor (TF) plays a major role in arterial thrombosis. TF is the main initiator of the coagulation cascade.
近年研究发现，组织因子(TF)是凝血瀑布的主要启动因素，在动脉血栓形成中起关键作用。
CONCLUSION: TFPI acted as an inhibitor of tissue factor pathway reflected the vascular endothelial injury and the states of coagulation indirectly in unstable angina progression.
结论：组织因子途径抑制物作为组织因子途径凝血过程的抑制物，间接反应了不稳定心绞痛发作过程中血管内皮的损伤和凝血状态。
The first antihemophilic factor (AHF) concentrate to treat coagulation disorders in hemophilia patients is developed through fractionation.
第一例抗血友病因子(AHF)经分离浓缩后用于治疗血友病患者的凝血功能障碍。
Result Uterine inertia in 12 cases (63.1%), placental factor 5 cases (26.3%), soft birth canal injury factors, 1 case (5.3%), coagulation dysfunction in 1 case (5.3%).
结果宫缩乏力12例（63.1%），胎盘因素5例（26.3%），软产道损伤因素1例（5.3%），凝血功能障碍1例（5.3%）。
Traditionally, the blood coagulation scheme has been divided into extrinsic and intrinsic pathways, converging at the point where factor X is activated.
传统，血液凝固计划已分为外在和内在的途径，在X因子被激活点汇合。
Tissue factor(TF)is the most important factor in the physiological coagulation process.
组织因子（TF）是生理性凝血过程中最重要的启动因子。
Conclusion Our results suggested that patients in the thrombotic and risk-factor group had activated coagulation and reduced fibrinolytic potential.
结论血栓组及高危因素组患者均有凝血激活及纤溶潜力明显降低。
Conclusion Our results suggested that patients in the thrombotic and risk-factor group had activated coagulation and reduced fibrinolytic potential.
结论血栓组及高危因素组患者均有凝血激活及纤溶潜力明显降低。
应用推荐